Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ceftazidime review.

R L Yost, R Ramphal

    Drug Intelligence & Clinical Pharmacy
    |July 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Ceftazidime, a new third-generation cephalosporin, shows unique effectiveness against Pseudomonas aeruginosa infections. It offers a favorable safety profile, similar to other cephalosporins, without the adverse effects of moxalactam or cefoperazone.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    First Attempt of Sequential Living Donor Liver and Hematopoietic Stem Cell Transplantation in a Child With Advanced Hepatocellular Carcinoma: Case Report.

    Transplantation proceedings·2016
    Same author

    Adolescent and young adult cancer: principles of care.

    Current oncology (Toronto, Ont.)·2016
    Same author

    Transcriptional response of mucoid Pseudomonas aeruginosa to human respiratory mucus.

    mBio·2012
    Same author

    Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.

    PharmacoEconomics·2004
    Same author

    Structural and genetic characterization of glycosylation of type a flagellin in Pseudomonas aeruginosa.

    Journal of bacteriology·2004
    Same author

    A position paper on the treatment of hospital acquired pneumonia (HAP): do we need guidelines?

    Acta clinica Belgica·2002
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Antimicrobial Agents

    Background:

    • Ceftazidime is a novel third-generation cephalosporin antibiotic.
    • Review of its properties is crucial for understanding its clinical utility.

    Purpose of the Study:

    • To review the chemistry, in vitro activity, adverse effects, and clinical indications of ceftazidime.
    • To assess its unique role in treating specific bacterial infections.

    Main Methods:

    • Literature review of ceftazidime's pharmacological and clinical data.
    • Comparative analysis of its efficacy and safety against other third-generation cephalosporins.

    Main Results:

    • Ceftazidime demonstrates unique efficacy against Pseudomonas aeruginosa.

    Related Experiment Videos

  • No superiority over other agents was found against Enterobacteriaceae, gram-positive cocci, or anaerobes.
  • Renal elimination and a half-life similar to ceftizoxime, cefoperazone, and moxalactam.
  • Shares the safety profile of cephalosporins, lacking prothrombin effects or disulfiram-like reactions.

    • Conclusions:

    • Ceftazidime holds a distinct position in treating Pseudomonas aeruginosa infections.
    • Its safety profile is comparable to other cephalosporins, making it a valuable therapeutic option.
    • Specific clinical indications for ceftazidime use are detailed.